よむ、つかう、まなぶ。
【参考資料３】【英版R4.1.17】Nippon AMR One Health Report (NAOR) 2020 (15 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_23261.html |
| 出典情報 | 国際的に脅威となる感染症対策関係閣僚会議 薬剤耐性ワンヘルス動向調査検討会（第9回 1／17）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Table 4. Trends in the proportion (%) of antimicrobial
ABPC
BP (-2013)
32
BP (2014-)
32
PIPC
128
128
4/128
4/128
CEZ**
32
8
CMZ
64
64
CTX**
64
4
CAZ**
32
16
CFPM
32
32
AZT**
32
16
IPM**
16
4
MEPM**
16
4
AMK
64
64
LVFX
8
8
TAZ/PIPC
2013
76.5
(17,362)
14.5
(18,029)
6.3
(5,568)
90.8
(17,945)
5.2
(14,452)
17.3
(17,992)
1.0
(8,909)
7.5
(14,639)
0.4
(16,881)
0.2
(10,249)
0.2
(18,369)
1.1
(18,111)
2014
77.1
(18,385)
14.5
(18,550)
4.9
(9,568)
94.0
(19,173)
84.8
(17,587)
28.3
(15,173)
24.3
(19,439)
1.2
(13,499)
15.8
(15,846)
1.7
(17,463)
0.9
(15,003)
0.2
(19,492)
1.0
(19,068)
-resistant Klebsiella (Enterobacter)* aerogenes
2015
78.9
(26,680)
14.2
(27,189)
4.8
(18,731)
93.7
(27,526)
86.8
(26,739)
30.7
(21,985)
25.2
(27,886)
1.1
(24,302)
17.5
(23,225)
1.9
(25,690)
0.8
(27,560)
0.1
(28,627)
0.9
(28,012)
2016
77.9
(29,228)
15.8
(29,852)
4.8
(21,767)
94.2
(30,088)
87.1
(29,681)
31.1
(23,572)
25.7
(30,388)
1.1
(27,146)
17.5
(25,023)
1.9
(28,307)
0.8
(31,311)
0.1
(31,338)
1.0
(30,451)
2017
79.1
(30,844)
17.1
(31,802)
5.7
(24,082)
94.5
(31,800)
88.0
(31,915)
32.9
(24,195)
26.7
(32,030)
1.3
(29.464)
18.0
(26,772)
1.9
(29,869)
0.8
(33,150)
0.1
(33,074)
0.9
(32,503)
2018
80.3
(32,746)
17.4
(33,048)
6.9
(26,272)
95.0
(33,996)
89.1
(34,051)
33.4
(25,493)
27.8
(34,142)
1.4
(32,216)
19.2
(28,281)
2.6
(31,288)
0.8
(35,448)
0.1
(35,214)
0.9
(34,383)
2019
80.5
(33,621)
18.9
(32,497)
6.9
(28,085)
94.7
(35,183)
89.5
(35,408)
34.2
(26,271)
28.5
(35,487)
1.5
(33,583)
20.2
(29,397)
2.3
(31,645)
0.8
(36,550)
0.1
(36,204)
0.9
(35,735)
The unit of BP is μg/mL.
Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.
-: Not under surveillance
*Enterobacter aerogenes has been renamed Klebsiella aerogenes (Int. J. Syst. Evol. Microbiol. 67, 502-504, 2017).
** CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP after 2014.
ⅳ. Pseudomonas aeruginosa
Table 5. Trends in the proportion (%) of antimicrobial-resistant Pseudomonas aeruginosa
BP (-2013)
128
BP (2014-)
128
2011
12.1
(114,950)
2012
11.9
(118,032)
2013
11.4
(122,581)
2014
10.8
(125,242)
2015
10.5
(181,977)
2016
10.5
(201,764)
2017
10.3
(205,165)
2018
10.0
(206,858)
2019
10.3
(214,513)
TAZ/
PIPC
4/128
4/128
-
-
9.0
(68,686)
8.8
(79,574)
8.8
(132,769)
8.4
(155,724)
8.3
(165,402)
8.1
(172,748)
8.4
(185,720)
CAZ
32
32
11.3
(116,596)
10.9
(120,473)
10.2
(124,864)
9.5
(126,718)
8.6
(180,479)
8.7
(199,597)
8.6
(202,025)
8.4
(203,554)
8.7
(210,892)
AZT
32
32
16.3
(96,435)
16.7
(100,964)
16.5
(105,681)
14.5
(107,167)
14.0
(146,841)
13.8
(158,737)
13.7
(162,952)
13.1
(162,365)
13.3
(167,331)
CFPM
32
32
9.7
(91,769)
8.9
(99,730)
8.0
(106,291)
7.5
(113,268)
6.6
(166,096)
6.5
(185,283)
6.3
(191,502)
6.0
(194,385)
5.9
(200,818)
IPM*
16
8
19.8
(112,596)
18.5
(116,193)
17.1
(119,979)
19.9
(119,323)
18.8
(168,471)
17.9
(186,380)
16.9
(188,981)
16.2
(188,778)
16.2
(195,183)
MEPM*
16
8
12.4
(109,453)
11.8
(113,996)
10.7
(119,330)
14.4
123,976)
13.1
(180,850)
12.3
(201,991)
11.4
(206,368)
10.9
(209,149)
10.6
(217,161)
GM
16
16
7.0
(111,137)
6.1
(115,612)
5.3
(118,592)
5.1
(117,421)
4.5
(165,777)
4.1
(182,343)
3.3
(184,453)
2.9
(184,135)
3.1
(190,296)
AMK
64
64
3.1
(116,876)
2.6
(121,289)
2.1
(126,023)
1.9
(128,923)
1.5
(185,327)
1.3
(204,892)
1.1
(208,098)
0.9
(209,413)
0.9
(217,512)
LVFX
8
8
16.8
(111,005)
16.3
(115,478)
14.5
(119,162)
13.0
(120,691)
12.0
(174,301)
11.6
(193,366)
10.8
(197,890)
10.2
(199,760)
9.8
(207,963)
PIPC
The unit of BP is μg/mL.
Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.
-: Not under surveillance
* CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP after 2014.
14
ABPC
BP (-2013)
32
BP (2014-)
32
PIPC
128
128
4/128
4/128
CEZ**
32
8
CMZ
64
64
CTX**
64
4
CAZ**
32
16
CFPM
32
32
AZT**
32
16
IPM**
16
4
MEPM**
16
4
AMK
64
64
LVFX
8
8
TAZ/PIPC
2013
76.5
(17,362)
14.5
(18,029)
6.3
(5,568)
90.8
(17,945)
5.2
(14,452)
17.3
(17,992)
1.0
(8,909)
7.5
(14,639)
0.4
(16,881)
0.2
(10,249)
0.2
(18,369)
1.1
(18,111)
2014
77.1
(18,385)
14.5
(18,550)
4.9
(9,568)
94.0
(19,173)
84.8
(17,587)
28.3
(15,173)
24.3
(19,439)
1.2
(13,499)
15.8
(15,846)
1.7
(17,463)
0.9
(15,003)
0.2
(19,492)
1.0
(19,068)
-resistant Klebsiella (Enterobacter)* aerogenes
2015
78.9
(26,680)
14.2
(27,189)
4.8
(18,731)
93.7
(27,526)
86.8
(26,739)
30.7
(21,985)
25.2
(27,886)
1.1
(24,302)
17.5
(23,225)
1.9
(25,690)
0.8
(27,560)
0.1
(28,627)
0.9
(28,012)
2016
77.9
(29,228)
15.8
(29,852)
4.8
(21,767)
94.2
(30,088)
87.1
(29,681)
31.1
(23,572)
25.7
(30,388)
1.1
(27,146)
17.5
(25,023)
1.9
(28,307)
0.8
(31,311)
0.1
(31,338)
1.0
(30,451)
2017
79.1
(30,844)
17.1
(31,802)
5.7
(24,082)
94.5
(31,800)
88.0
(31,915)
32.9
(24,195)
26.7
(32,030)
1.3
(29.464)
18.0
(26,772)
1.9
(29,869)
0.8
(33,150)
0.1
(33,074)
0.9
(32,503)
2018
80.3
(32,746)
17.4
(33,048)
6.9
(26,272)
95.0
(33,996)
89.1
(34,051)
33.4
(25,493)
27.8
(34,142)
1.4
(32,216)
19.2
(28,281)
2.6
(31,288)
0.8
(35,448)
0.1
(35,214)
0.9
(34,383)
2019
80.5
(33,621)
18.9
(32,497)
6.9
(28,085)
94.7
(35,183)
89.5
(35,408)
34.2
(26,271)
28.5
(35,487)
1.5
(33,583)
20.2
(29,397)
2.3
(31,645)
0.8
(36,550)
0.1
(36,204)
0.9
(35,735)
The unit of BP is μg/mL.
Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.
-: Not under surveillance
*Enterobacter aerogenes has been renamed Klebsiella aerogenes (Int. J. Syst. Evol. Microbiol. 67, 502-504, 2017).
** CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP after 2014.
ⅳ. Pseudomonas aeruginosa
Table 5. Trends in the proportion (%) of antimicrobial-resistant Pseudomonas aeruginosa
BP (-2013)
128
BP (2014-)
128
2011
12.1
(114,950)
2012
11.9
(118,032)
2013
11.4
(122,581)
2014
10.8
(125,242)
2015
10.5
(181,977)
2016
10.5
(201,764)
2017
10.3
(205,165)
2018
10.0
(206,858)
2019
10.3
(214,513)
TAZ/
PIPC
4/128
4/128
-
-
9.0
(68,686)
8.8
(79,574)
8.8
(132,769)
8.4
(155,724)
8.3
(165,402)
8.1
(172,748)
8.4
(185,720)
CAZ
32
32
11.3
(116,596)
10.9
(120,473)
10.2
(124,864)
9.5
(126,718)
8.6
(180,479)
8.7
(199,597)
8.6
(202,025)
8.4
(203,554)
8.7
(210,892)
AZT
32
32
16.3
(96,435)
16.7
(100,964)
16.5
(105,681)
14.5
(107,167)
14.0
(146,841)
13.8
(158,737)
13.7
(162,952)
13.1
(162,365)
13.3
(167,331)
CFPM
32
32
9.7
(91,769)
8.9
(99,730)
8.0
(106,291)
7.5
(113,268)
6.6
(166,096)
6.5
(185,283)
6.3
(191,502)
6.0
(194,385)
5.9
(200,818)
IPM*
16
8
19.8
(112,596)
18.5
(116,193)
17.1
(119,979)
19.9
(119,323)
18.8
(168,471)
17.9
(186,380)
16.9
(188,981)
16.2
(188,778)
16.2
(195,183)
MEPM*
16
8
12.4
(109,453)
11.8
(113,996)
10.7
(119,330)
14.4
123,976)
13.1
(180,850)
12.3
(201,991)
11.4
(206,368)
10.9
(209,149)
10.6
(217,161)
GM
16
16
7.0
(111,137)
6.1
(115,612)
5.3
(118,592)
5.1
(117,421)
4.5
(165,777)
4.1
(182,343)
3.3
(184,453)
2.9
(184,135)
3.1
(190,296)
AMK
64
64
3.1
(116,876)
2.6
(121,289)
2.1
(126,023)
1.9
(128,923)
1.5
(185,327)
1.3
(204,892)
1.1
(208,098)
0.9
(209,413)
0.9
(217,512)
LVFX
8
8
16.8
(111,005)
16.3
(115,478)
14.5
(119,162)
13.0
(120,691)
12.0
(174,301)
11.6
(193,366)
10.8
(197,890)
10.2
(199,760)
9.8
(207,963)
PIPC
The unit of BP is μg/mL.
Figures in parentheses indicate the number of bacterial strains that were tested for antimicrobial susceptibility.
-: Not under surveillance
* CLSI (2007) (M100-S17) Criteria was applied to determine the BP up to 2013. CLSI (2012) (M100-S22) Criteria was applied to determine BP after 2014.
14